Blue-light cystoscopy in the evaluation of non-muscle-invasive bladder cancer
- 15 November 2013
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Urology
- Vol. 6 (1) , 25-33
Abstract
Bladder carcinoma is the most common malignancy of the urinary tract. Two distinct groups can be identified: non-muscle-invasive bladder carcinoma (NMIBC) and muscle-invasive bladder carcinoma. At initial resection about 75–85% of the patients will be diagnosed with NMIBC. This subgroup has a recurrence rate up to 70–80%, and a subsequent chance of disease progression. This means that patients with NMIBC require adequate treatment and thorough follow up. This high recurrence rate also means that apparently current diagnosis and treatment can be improved. It is thought that photodynamic diagnosis, by the use of a photosensitizing drug and blue-light cystoscopy, can improve the detection of tumor and therefore affect outcome for patients with NMIBC. In this paper we will discuss the role of blue-light cystoscopy in NMIBC in different aspects of the disease by reviewing the latest literature.Keywords
This publication has 40 references indexed in Scilit:
- Long-Term Decrease in Bladder Cancer Recurrence with Hexaminolevulinate Enabled Fluorescence CystoscopyJournal of Urology, 2012
- A comparison of hexaminolevulinate (Hexvix®) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational studySurgical Endoscopy, 2012
- Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladderUrologic Oncology: Seminars and Original Investigations, 2012
- Efficacy and Safety of Hexaminolevulinate Fluorescence Cystoscopy in the Diagnosis of Bladder CancerKorean Journal of Urology, 2012
- Treatment changes and long‐term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non‐muscle‐invasive bladder cancer (NMIBC)?BJU International, 2011
- Economic aspects of bladder cancer: what are the benefits and costs?World Journal of Urology, 2009
- LONG-TERM BENEFIT OF 5-AMINOLEVULINIC ACID FLUORESCENCE ASSISTED TRANSURETHRAL RESECTION OF SUPERFICIAL BLADDER CANCER: 5-YEAR RESULTS OF A PROSPECTIVE RANDOMIZED STUDYJournal of Urology, 2005
- IMPROVED DETECTION AND TREATMENT OF BLADDER CANCER USING HEXAMINOLEVULINATE IMAGING: A PROSPECTIVE, PHASE III MULTICENTER STUDYJournal of Urology, 2005
- Comparison of Aminolevulinic Acid and Hexylester Aminolevulinate Induced Protoporphyrin IX Distribution in Human Bladder CancerJournal of Urology, 2003
- FLUORESCENCE ENDOSCOPY WITH 5-AMINOLEVULINIC ACID REDUCES EARLY RECURRENCE RATE IN SUPERFICIAL BLADDER CANCERJournal of Urology, 2001